Vertex Newswire

Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 287 in Vertex

  1. Premarket Biotech Digest: Approvals And Stock Prices, VSAR Hold Lifted, Gilead's TAFRead the original story w/Photo

    6 hrs ago | Seeking Alpha

    Yesterday's Vertex Orkambi approval saw a surge in its shares, up 4% since the previous day's closing. Because it is a $30 billion company, with stock price hovering around $120, this wasn't a lot.

    Comment?

  2. Premarket Biotech Digest: Approvals And Stock Prices, VSAR Hold Lifted, Gilead's TAFRead the original story w/Photo

    7 hrs ago | Seeking Alpha

    Yesterday's Vertex Orkambi approval saw a surge in its shares, up 4% since the previous day's closing. Because it is a $30 billion company, with stock price hovering around $120, this wasn't a lot.

    Comment?

  3. 'It's a game changer,' new drug to treat cystic fibrosis holds promiseRead the original story w/Photo

    16 hrs ago | WTVR Richmond

    ... Only 2,000 people in the United States have a certain mutation that responds to the drug. Orkambi, manufactured by Vertex Pharmaceuticals, extends the treatment to thousands more CF patients because it targets patients who have two copies of the ...

    Comment?

  4. FDA Approves Orkambi (Lumacaftor/Ivacaftor) for Cystic FibrosisRead the original story

    Yesterday | P&T Community

    ... of the disease in people who have two copies of a specific mutation. Orkambi (lumacaftor 200 mg/ivacaftor 125 mg, Vertex Pharmaceuticals) is indicated for the treatment of CF in patients 12 years of age and older who have the F 508del mutation, ...

    Comment?

  5. Premarket Biotech Digest: Arrowhead Initiates Dosing, Vertex Orkambi Approval, Insider SalesRead the original story w/Photo

    Yesterday | Seeking Alpha

    ... HSP ). The U.S. Court for the Federal Circuit Court ruled that the company's patents covering Angiomax are invalid. Vertex (NASDAQ: VRTX ) received an approval for Orkambi, "a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane ...

    Comment?

  6. 14 big companies facing steep lossesRead the original story w/Photo

    Yesterday | USA Today

    There are 14 companies in the Standard & Poor's 500, including Anadarko Petroleum , biotech Vertex Pharmaceuticals and online retailer Amazon.com that are expected to post adjusted losses during the second-quarter, according to a USA TODAY analysis of data from S&P Capital IQ. Investors are braced for a not-so-hot period of corporate profits.

    Comment?

  7. FDA Clears Drug for Leading Form of Cystic FibrosisRead the original story w/Photo

    Thursday Jul 2 | The Daily News

    ... price more than $250,000 for a year's treatment. The Food and Drug Administration cleared the twice-a-day pill from Vertex Pharmaceuticals for a variation of cystic fibrosis that affects about 8,500 people in the U.S. who are 12 years and older. The ...

    Comment?

  8. US stocks end slightly lowerRead the original story

    Thursday Jul 2 | The Standard

    ... on the stock given its lofty valuation and the significant foreign exchange headwinds facing many DuPont businesses. Vertex Pharmaceuticals jumped by 4 percent after announcing that the US Food and Drug Administration approved its Orkambi drug to ...

    Comment?

  9. Stocks Sag After Weak NFP Report, Greece Worries WeighRead the original story w/Photo

    Thursday Jul 2 | Minyanville

    ... all claims related to its 2010 oil spill for $18.7 billion. The stock rose 5.1% as the company can stomach the blow. Vertex Pharmaceuticals (VRTX) rallied 4.0% to $131.26 after receiving FDA approval for its Orkambi cystic fibrosis treatment. On the ...

    Comment?

  10. US stocks end lower after mixed jobs reportRead the original story w/Photo

    Thursday Jul 2 | Channelnewsasia.com

    ... on the stock given its lofty valuation and the significant foreign exchange headwinds facing many DuPont businesses. Vertex Pharmaceuticals jumped 4.0 per cent after announcing that the US Food and Drug Administration approved its Orkambi drug to ...

    Comment?

  11. FDA OKs Drug That Can Reverse Cystic Fibrosis Lung DamageRead the original story w/Photo

    Thursday Jul 2 | News Max

    ... price - more than $250,000 for a year's treatment. The Food and Drug Administration cleared the twice-a-day pill from Vertex Pharmaceuticals for a variation of cystic fibrosis that affects about 8,500 people in the U.S. who are 12 years and older. ...

    Comment?

  12. Vertex Pharmaceuticals: Now That's an ApprovalRead the original story w/Photo

    Thursday Jul 2 | Barron's

    Shares of Vertex Pharmaceuticals are soaring after the FDA approved its cystic-fibrosis drug . UBS analyst Matthew Roden says the decision should help push Vertex "towards profitability."

    Comment?

  13. FDA approves Vertex treatment for cystic fibrosisRead the original story w/Photo

    Thursday Jul 2 | Boston.com

    Vertex Pharmaceuticals Inc. won long-awaited US regulatory approval Thursday for a genetic-based medicine that eventually could treat roughly half of the estimated 30,000 Americans who suffer from the life-threatening lung disease cystic fibrosis. Company executives priced the two-drug therapy, called Orkambi, at $259,000 per patient annually and said they hoped to begin shipping the treatment to about 295 care centers across the United States within days.

    Comment?

  14. The Wall Street Journal: Vertex gets Fda Ok for cystic-fibrosis drugRead the original story w/Photo

    Thursday Jul 2 | MarketWatch

    Vertex Pharmaceuticals Inc.'s experimental cystic-fibrosis drug Orkambi, which treats the most common mutation of the disease, received U.S. regulatory approval on Thursday. The drug is a twice-daily oral tablet for patients 12 years and older that Vertex said would be available within days.

    Comment?

  15. FDA approves drug that eventually could help half of people with cystic fibrosisRead the original story w/Photo

    Thursday Jul 2 | The Washington Post

    Viji Arumugam, a scientist at Vertex Pharmaceuticals, works in her laboratory in San Diego earlier this year. The company, which on Thursday won approval for a second drug to treat the underlying cause of cystic fibrosis, hopes to have treatments for roughly 90 percent of patients with the disease by around 2020.

    Comment?

  16. Inside Vertex's headquartersRead the original story w/Photo

    Feb 4, 2014 | Boston.com

    ... dozens of their colleagues gather for the weekly beer hour. Welcome to the new $800 million headquarters of Vertex Pharmaceuticals Inc. on the South Boston Waterfront, where about 1,200 of the drug maker's research and commercial employees have been ...

    Comment?

  17. Is There Opportunity in Personalized Medicine?Read the original story

    Thursday Jul 2 | Morningstar

    ... its expected earnings for the next 12 months and is currently trading at its fair value, according to Morningstar. Vertex Pharmaceuticals, maker of Kalydeco, sells for 29.8 times expected earnings and also trades around its fair value. Foundation ...

    Comment?

  18. Why is Celgene So Darn Expensive?Read the original story w/Photo

    Tuesday Jun 30 | Barron's

    With the $1B payment to Juno , many investors have re-awakened the question as to whether this is worthy of constantly being "backed out" of non-GAAP EPS and have inquired on how big the total annual payments are now running for Celgene out to biotech partners each year and what the "conservative" EPS would look like if Celgene included all the upfront payments in the non-GAAP EPS. As a reminder, Celgene does not include upfronts in non-GAAP EPS whereas Biogen, Gilead Sciences, Regeneron Pharmaceuticals , Vertex Pharmaceuticals , etc do which reduces non-GAAP EPS).

    Comment?

  19. Vertex Poised to Become Profitable Following Expected FDA Approval of OrkambiRead the original story

    Monday Jun 29 | BioSpace

    June 30, 2015 By Alex Keown and Riley McDermid , BioSpace.com Breaking News Staff BOSTON - Vertex Pharmaceuticals is anxiously waiting for regulatory approval of its newest cystic fibrosis medication Orkambi, a treatment which is widely expected to have a broad impact on the cystic fibrosis market - and a treatment widely expected to sharply boost revenues. The U.S. Food and Drug Administration is expected to approve the medication for market later this week.

    Comment?

  20. Here are the nine highest-paid life science executives in 2014Read the original story w/Photo

    Friday Jun 26 | Business Journal

    ... The issue of high-paid CEOs in the biotech industry gained some attention recently when a majority of stockholders at Vertex Pharmaceuticals (Nasdaq: VRTX) voted against the pay package given to CEO Jeff Leiden in a non-bonding vote. The company has ...

    Comment?